Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ?50%: The EMPOWER-Lung 1 study için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ?50%: The EMPOWER-Lung 1 study | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Mayıs 2024 | 0 |
| Haziran 2024 | 0 |
| Temmuz 2024 | 0 |
| Ağustos 2024 | 0 |
| Eylül 2024 | 0 |
| Ekim 2024 | 0 |
| Kasım 2024 | 0 |
